Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies

Comparing Azole Plasma Trough Levels in Lung Transplant Recipients

(2017) Daniela Stelzer et al.   THERAPEUTIC DRUG MONITORING

Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant

(2016) Aaron N. Pham et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increased inhibition of cytochrome P450 3A4 with the tablet formulation of posaconazole

(2016) A. Petitcollin et al.   Drug Metabolism and Pharmacokinetics

Clinical hepatotoxicity associated with antifungal agents

(2016) Ioannis Kyriakidis et al.   Expert Opinion On Drug Safety

Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension

(2015) Urshila Durani et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies

(2015) Aaron Cumpston et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease

(2015) Oliver A. Cornely et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis

(2015) Marisa H. Miceli et al.   MYCOSES

Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia

(2014) Rafael F. Duarte et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Switching from Posaconazole Suspension to Tablets Increases Serum Drug Levels in Leukemia Patients without Clinically Relevant Hepatotoxicity

(2014) Dong Sik Jung et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

(2013) H. R. Ashbee et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Niveau de preuve du suivi thérapeutique pharmacologique du posaconazole

(2011) Sandrine Lefeuvre et al.   THERAPIE

Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of four triazole antifungal agents in human plasma

(2010) Marie-Clémence Verdier et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma

(2010) S H Jang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS